CBER Cuts Device Review Backlog to 17% - Device Action Plan Update
This article was originally published in The Gray Sheet
Executive Summary
FDA's Center for Biologics Evaluation and Review has taken first action within the statutory timeframe on 11 medical device premarket submissions received in the past six months.